moxifloxacin has been researched along with voriconazole in 15 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (voriconazole) | Trials (voriconazole) | Recent Studies (post-2010) (voriconazole) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 4,390 | 219 | 2,678 |
| Protein | Taxonomy | moxifloxacin (IC50) | voriconazole (IC50) |
|---|---|---|---|
| Cytochrome P450 2C9 | Homo sapiens (human) | 8.4 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 8.7 | |
| Cholesterol 24-hydroxylase | Homo sapiens (human) | 0.0345 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kim, SY; Lee, YC; Yang, J | 1 |
| Arnalich-Montiel, F; López-Arencibia, A; Lorenzo-Morales, J; Martín-Navarro, CM; Piñero, JE; Valladares, B | 1 |
| Binder, PS; Kontadakis, GA; Kymionis, GD; Pallikaris, IG; Plaka, AD; Tsoulnaras, KI | 1 |
| Dhingra, D; Hemanth, V; Jain, AK; Kaur, S; Malhotra, C; Sharma, SP | 1 |
| Arguello, RA; Chevez-Barrios, P; Divatia, MK; Matoba, AY | 1 |
| Chhabria, M; Kudaravalli, P; Lesho, E; Pendela, VS | 1 |
| Hazarika, M; Prajna, NV; Senthilkumari, S | 1 |
| Aragona, P; Biondo, C; Inferrera, L; Postorino, EI; Roszkowska, AM; Severo, AA | 1 |
| Cai, DH; Fang, XL; Wang, J | 1 |
| Agrawal, S; Bhatta, RS; Bisen, AC; Biswas, A; Mishra, A; Sanap, SN; Verma, SK | 1 |
| Agrawal, S; Bhatta, RS; Bisen, AC; Biswas, A; Choudhury, AD; Kumar, M; Mishra, A; R, HG; Sanap, SN | 1 |
2 review(s) available for moxifloxacin and voriconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combined Phialemonium curvatum and Acanthamoeba Keratitis: The Importance of Early Diagnosis and Specific Therapy.
Topics: Acanthamoeba Keratitis; Administration, Ophthalmic; Anti-Bacterial Agents; Antifungal Agents; Ascomycota; Biguanides; Disinfectants; Drug Therapy, Combination; Early Diagnosis; Eye Infections, Fungal; Female; Humans; Keratitis; Microscopy, Confocal; Middle Aged; Moxifloxacin; Mycoses; Ophthalmic Solutions; Slit Lamp Microscopy; Voriconazole | 2021 |
13 other study(ies) available for moxifloxacin and voriconazole
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Safety of moxifloxacin and voriconazole in corneal storage media on porcine corneal endothelial cells.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Cell Count; Cell Survival; Chondroitin Sulfates; Complex Mixtures; Cornea; Cryopreservation; Culture Media, Serum-Free; Dextrans; Endothelium, Corneal; Fluoroquinolones; Gentamicins; Moxifloxacin; Organ Preservation Solutions; Pyrimidines; Quinolines; Swine; Tissue Preservation; Triazoles; Voriconazole | 2010 |
Evaluation of the in vitro activity of commercially available moxifloxacin and voriconazole eye-drops against clinical strains of Acanthamoeba.
Topics: Acanthamoeba castellanii; Amebicides; Amphotericin B; Animals; Anti-Bacterial Agents; Antifungal Agents; Aza Compounds; Chlorhexidine; Colorimetry; Drug Combinations; Fluoroquinolones; HeLa Cells; Humans; Macrophages; Mice; Moxifloxacin; Ophthalmic Solutions; Parasitic Sensitivity Tests; Pyrimidines; Quinolines; Triazoles; Voriconazole | 2013 |
Femtosecond Laser-Assisted Intra-Corneal Drug Delivery.
Topics: Abscess; Aged; Anti-Bacterial Agents; Antifungal Agents; Corneal Stroma; Corneal Surgery, Laser; Corneal Ulcer; Drug Delivery Systems; Drug Implants; Drug Therapy, Combination; Eye Infections, Fungal; Female; Fluoroquinolones; Humans; Lasers, Excimer; Moxifloxacin; Voriconazole | 2015 |
In vivo confocal microscopic characteristics of microsporidial keratoconjunctivitis in immunocompetent adults.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antifungal Agents; Drug Therapy, Combination; Eye Infections, Fungal; Female; Fluoroquinolones; Humans; Immunocompetence; Keratoconjunctivitis; Male; Microscopy, Confocal; Microsporidia; Microsporidiosis; Moxifloxacin; Risk Factors; Voriconazole; Young Adult | 2017 |
Clinically Significant Enhancement of Voriconazole Efficacy by Moxifloxacin and Gentamicin in Fungal Keratitis.
Topics: Anti-Bacterial Agents; Antifungal Agents; Drug Therapy, Combination; Eye Infections, Fungal; Fluoroquinolones; Gentamicins; Humans; Keratitis; Male; Middle Aged; Moxifloxacin; Treatment Outcome; Voriconazole; Young Adult | 2018 |
Case Report: A Polymicrobial Vision-Threatening Eye Infection Associated with Polysubstance Abuse.
Topics: Administration, Ophthalmic; Adult; Anti-Inflammatory Agents; Antioxidants; Ascorbic Acid; Ceftazidime; Cocaine; Cocaine-Related Disorders; Coinfection; Dopamine Uptake Inhibitors; Doxycycline; Endophthalmitis; Female; Gram-Positive Bacterial Infections; Humans; Keratitis; Kingella; Linezolid; Moxifloxacin; Neisseriaceae Infections; Ophthalmic Solutions; Prednisone; Propionibacterium acnes; Streptococcal Infections; Streptococcus; Substance Abuse, Intravenous; Tobramycin; Vancomycin; Voriconazole | 2020 |
Drug reservoir function of voriconazole impregnated human amniotic membrane: An
Topics: Amnion; Antifungal Agents; Eye Infections, Fungal; Humans; Moxifloxacin; Pharmaceutical Preparations; Voriconazole | 2021 |
Successful treatment of Talaromyces marneffei pneumonia in a HIV-negative renal transplantation recipient: A case report.
Topics: Antifungal Agents; HIV Infections; Humans; Kidney Transplantation; Moxifloxacin; Mycoses; Pneumonia; Tacrolimus; Talaromyces; Voriconazole | 2022 |
Simultaneous estimation of voriconazole, moxifloxacin, and pirfenidone in rabbit lacrimal matrix using LC-MS/MS: an application to preclinical ocular pharmacokinetics.
Topics: Animals; Chromatography, Liquid; Moxifloxacin; Rabbits; Reproducibility of Results; Tandem Mass Spectrometry; Voriconazole | 2023 |
A QbD-led simple and sensitive RP-UHPLC method for simultaneous determination of moxifloxacin, voriconazole, and pirfenidone: An application to pharmaceutical analysis.
Topics: Chromatography, High Pressure Liquid; Moxifloxacin; Pharmaceutical Preparations; Voriconazole | 2023 |